Scientists are carefully examining the drug , a investigational therapeutic targeting tau tangles , a significant hallmark of Alzheimer's . Unlike many prior trials focused on amyloid plaques, Semorinemab seeks to selectively diminish these damaging tau formations in the brain . Early clinical resu